New hope for prostate cancer: could a short hormone boost stop spread?

NCT ID NCT06654336

Recruiting now Disease control Sponsor: Ontario Clinical Oncology Group (OCOG) Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study looks at men whose prostate cancer has come back in a few spots after radiation therapy. It tests whether adding a hormone-blocking drug (ELIGARD) to targeted treatment helps keep the cancer from growing longer than targeted treatment alone. About 162 men will take part, and they will be followed for 3 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H1T2M4, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Juravinski Cancer Centre
RECRUITING

Hamilton, Ontario, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
The Ottawa Hospital Regional Cancer Centre
NOT_YET_RECRUITING

Ottawa, Ontario, K1H8L6, Canada

Contact

Conditions

Explore the condition pages connected to this study.

CASTRATION SENSITIVE PROSTATE CANCER PROSTATE ADENOCARCINOMA